BAYER AG - 500 Beiträge pro Seite

[ER22]

Meine Empfehlung für heute BAYER

Buchwert je Aktie 23 €

Die Zeit der schlechten Nachrichten ist vorbei

Buy on bad news!

wenn man mehrere Empfehlungen vergleicht

liegt das Kursziel zwischen 27 und 30 €

sehr konservativ, aber mit wenig risiko

[markusJ]

Bin dabei --> allerdings mit dem 739503 OS

[williaktie]

@markus,bin drin in 712249 kk.0,10
was würdest du machen.? laufen lassen.?
mfg

[ER22]

bin auch drin mit 714521, find ich interessanter

Basispreis 30 €

[daniel]

wie findet ihr 673937

[ER22]

auf alle fälle laufen lassen!

die haben ihre schlechte zeit erst hintersich

ziel mind. 25 € kurzfristige

somit verkaufst du zwar mit 60 bis 50 % gewinn

aber stell dir deinen gewinn mal bei 25 € vor!!!

ich freu mich drauf!!!!!!!!!!!!!!11

[williaktie]

@Err22,dann wollen wir hoffen das es so kommt. verkaufst du dann alles,oder nimmst du nur" die Gewinne mit.
mfg

[ER22]

das kann ich jetzt noch nicht sagen!

kommt auf den moment an.

welche stimmung im markt ist!
wie die charttechnik bei dieser marke aussieht!
welche politischen und wirtschaftlichen daten anstehen!

we will see!

meld mich morgen wieder!!!!!!!!!!!!!

[887766]

Ich bin mir auch ziemlich sicher, Bayer sieht alte Aktienkurse wieder.

[merx]

Hallo Bayer und Bayernfan`s,

was meint Ihr zu 637 505.

massive Eindeckung erfolgte zu 0,039.


time will tell.

Good time with b a y e r


any comments ???????


m e r x

[ER22]

der schein ist auch nicht schlecht (637505)
ist halt von ubs warburg
die haben oft wenig umsätze und man bekommt nich so oft
kurse

oder hast du bessere erfahrung?

dann hoffen wir mal das diese kurzfristige dynamic
im markt bleibt (vorallem heute)
damit wir am mo und die nächste woche auch noch steigende
kurse sehen

wenn das eintritt, können wir dei 25 € nächste woche schon sehen!

i hope so!!!!!!!!!!!!

[tradingfuchs]

Ja, das sieht gut aus. Bayer bricht z.Zt. seinen mittelfristigen Abwärtstrend, die 35-Tage-Linie dreht langsam nach oben. Auf kurzfristige Sicht zählt die Aktie zu den Outperformern des Marktes. Mittelfristig besteht noch Nachholpotenzial. Auf der anderen Seite hat sich m.E. aufgrund der starken Dynamik der letzten Tage nun aber auch kurzfristiges Rückschlagspotenzial aufgebaut.

Quelle: http://www.traducer.de/star/include/acsg_c.htm

Gruß tf

[merx]

schaut mal was da Reuters meldet:

Reuters
Glaxo tipped to buy Bayer`s drug unit-report
Saturday November 16, 8:45 pm ET


LONDON, Nov 17 (Reuters) - The Independent on Sunday newspaper has tipped GlaxoSmithKline Plc as a potential buyer of the ailing pharmaceutical arm of Germany`s Bayer AG.
Glaxo is said to be in "significant talks" over a sale of Bayer`s drugs operations, the newspaper said, citing sources close to the UK drugmaker.

ADVERTISEMENT


Glaxo, along with Switzerland`s Roche (ROCZg.VX), has been widely touted as a buyer of Bayer`s drugs unit after the German firm said on Tuesday it had dropped a key demand for a majority stake in a pharmaceutical partnership, opening the way for it to find a partner for its struggling drugs business sooner than expected.

Gaining control of the ailing drugs business would cost around eight billion euros ($8.06 billion) and would provide Glaxo with several products, including the anthrax drug Cipro, as well as boosting Glaxo`s product development pipeline, the newspaper said.

No one at GlaxoSmithKline was immediately available for comment.

Glaxo and Bayer have a co-promotion and co-development deal for impotence drug Levitra, which would rival Pfizer Inc.`s (NYSE:PFE - News) blockbuster Viagra. Levitra, known generically as vardenafil, originally was developed by Bayer.

The troubles at Bayer`s drugs business stem mainly from last year`s costly recall of top-selling cholesterol drug Baycol.



Gruß

merx

[merx]

und noch ne Meldung:

Reuters
UPDATE - Glaxo and others seen circling Bayer`s drugs unit
Sunday November 17, 11:01 am ET
By Ben Hirschler, European Pharmaceuticals Correspondent


(Adds comment from industry sources, analyst, background)
LONDON, Nov 17 (Reuters) - GlaxoSmithKline Plc (London:GSK.L - News) is among a number of companies considering a bid for the ailing pharmaceutical arm of Germany`s Bayer AG (XETRA:BAYG.DE - News), industry sources said on Sunday.

ADVERTISEMENT


"A lot of companies are running their slide rules over this, but on a scale of `hot` to `cold` it`s still only at the `lukewarm` stage," said one person familiar with the situation.

Bayer, whose scientists invented aspirin, effectively put its drugs unit up for sale last week by announcing it now no longer insisted on holding a majority in any partnership involving the business.

The move opens the door to a deal with leading global pharmaceutical companies that would not have considered taking a minority stake.

GSK, Europe`s biggest drugs company, is in some ways the most obvious partner for Bayer, since the two companies already have a joint marketing deal for a promising anti-impotence drug developed by the German firm.

Bayer and Glaxo believe they have a potential $1 billion a year product in Levitra, or vardenafil, which will rival Pfizer Inc`s (NYSE:PFE - News) Viagra in the fast-growing erectile dysfunction market, following its planned market entry next year.

"The rationale for Glaxo would be to capture the full economic benefit of vardenafil," said Jeff Stevens, industry analyst at JP Morgan.

In this respect, a GSK/Bayer tie-up could parallel Pfizer`s acquisition of Pharmacia Corp (NYSE:PHA - News) earlier this year, which was driven by Pfizer`s desire to win full control of best-selling arthritis drug Celebrex.

COST CUTTING

The is little else, however, in the Bayer new drug pipeline and GSK would have to engage in some heavy cost cutting at the loss-making Bayer unit to ensure any deal boosted earnings, other analysts said.

"Whether GSK goes for it will, I think, depend on how cheaply they can get it for," said one.

Britain`s Independent on Sunday newspaper earlier reported that GSK was in "significant talks" over acquiring control of Bayer`s drugs operations for around eight billion euros ($8.06 billion).

A spokesman for GSK declined to comment on the report while officials at Bayer were not immediately available.

Bayer`s once mighty drugs operations were brought low by last year`s costly recall of top-selling cholesterol drug Baycol, following dozens of deaths due to a rare muscle weakening side effect.

The loss of Baycol coupled with production problems involving haemophilia treatment Kogenate left the German chemicals and drugs conglomerate struggling to stay a key player in the pharmaceuticals market, despite hot demand for its anthrax antibiotic Cipro.

One industry insider familiar with Bayer told Reuters last week that no deal was imminent for the drugs unit. But he cited GSK, Switzerland`s Roche Holding AG (ROCZg.VX) and U.S.-based Bristol-Myers Squibb Co (NYSE:BMY - News) as possible partners.

Roche had already been rumoured as a possible partner for Bayer a year ago, before Bayer signed its deal for vardenafil with GSK. But the Swiss company`s head of strategic marketing, Charles Sabbah, said last week Roche was more interested in acquiring products than companies.

Some analysts have also suggested Franco-German Aventis SA (Paris:AVEP.PA - News) as a possible German solution for Bayer.

Gruß

merx